Prime Medicine PRME Proceeds from Maturities, Prepayments and Calls of Short-Term Investments
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's proceeds from maturities, prepayments and calls of short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's proceeds from maturities, prepayments and calls of short-term investments?
- Prime Medicine (PRME) reported proceeds from maturities, prepayments and calls of short-term investments of $50.89M in Q1 2026.
- How has Prime Medicine's proceeds from maturities, prepayments and calls of short-term investments changed year-over-year?
- Prime Medicine's proceeds from maturities, prepayments and calls of short-term investments increased by 1596.3% year-over-year, from $3M to $50.89M.
- What is the long-term trend for Prime Medicine's proceeds from maturities, prepayments and calls of short-term investments?
- Over 3 years (2022 to 2025), Prime Medicine's proceeds from maturities, prepayments and calls of short-term investments has grown at a 1.0% compound annual growth rate (CAGR), from $93M to $95.78M.